Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.
Akeso defeats the "Medicine King".
The success of innovative drugs is not only a technological success, but also a financial success.
BeiGene Stock Rises on FDA Fast Track Tag for Investigational Cancer Therapy
Yasheng Pharmaceuticals has also landed | JIANZHI Research
One step closer to regular profitability.
WuXi AppTec's joint venture, Pharmapace, has gained benefits from the ADC industry. | Jianzhi Research
Net profit increased by 175% year-on-year, exceeding expectations, but the market's extreme pessimism has not yet been eliminated.
The growth rate of all channels of dressing in the second half of the year may be slightly lower than that in the first half. Juzi Biotech stated that it will continue to expand the number of terminal stores. Earnings conference coverage.
At the earnings conference, Juzi Biotech predicted that products such as wrinkle fillers may obtain registration certificates in the first quarter of next year. The company's secretary, Yan Yubo, stated that due to the impact of online growth, the overall growth rate of all channels of dressings may be slightly lower than the first half of the year. The company's CFO, Zhang Huijuan, expects that the growth rate in the CS/KA channel will further slow down in the second half of the year.
Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.
Zai Lab Q2 2024 GAAP Loss Per ADS $(0.82) Misses $(0.70) Estimate, Sales $100.504M Beat $93.136M Estimate
WuXi AppTec mid-year analysis: Biomedical industry recovery is already underway | Jian Zhi Research
Looking at the mid-year reports from CXO leaders such as WuXi AppTec, IQVIA, and Lonza, hand orders are exceeding expectations. Among them, WuXi AppTec's new hand order amount (excluding COVID-19 business) increased by 33.2%, far beyond the market expectations. The recovery trend of overseas biotech companies has already emerged.
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
Zai Lab Analyst Ratings
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
WuXi AppTec Goes Ex Dividend Tomorrow
Hangzhou Tigermed Consulting Goes Ex Dividend Tomorrow
The total relief rate of Xidacilone race reaches 94%, and sales growth is expected.
On June 4th, Genscript Bio (1548.HK, referred to as "Genscript") announced that its subsidiary, Legend Biotech (LEGN.O), released the results of Phase 2 CARTITUDE-2 (Siltuximab) Cohort D study for the treatment of multiple myeloma patients for the first time at the ASCO Annual Meeting.
Summit Therapeutics Falls Almost 20% as it Returns Part of Last Week's 280%+ Rally
Did Kang Fang Bio, which collapsed in the past, turn around with “head to head” with K medicine?
Investing in health requires a strong heart.
Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin
On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.
BeiGene Says BRUKINSA Data At American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago Underscore Differentiated Clinical Profile For Treatment Of CLL And SLL
Organon Says European Medicines Agency (Ema) Validates Henlius And Organon Filings For Prolia And Xgeva (Denosumab) Biosimilar Candidate HlX14